TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23445566

Group type: EXPERIMENTAL
Intervention: Educational intervention with vocal training exercises and vocal hygiene habits (experimental group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Guidance on vocal hygiene habits (control group)
Number of subjects: 70
Study: 20961474

Group type: EXPERIMENTAL
Intervention: Wellness Workshop (WW) CD‐ROM + Treatment as Usual (TAU)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 191
Study: 19271112

Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anti-HBc negative patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-HBc positive patients with HBV-DNA
Number of subjects: 100
Study: 17298711

Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (30% energy from fat)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Low-fat diet (20% energy from fat)
Number of subjects: 89
Study: 14745389

Group type: EXPERIMENTAL
Intervention: 1% lidocaine sprayed on the major duodenal papilla
Number of subjects: 326

Group type: COMPARATOR
Intervention: Normal saline solution sprayed on the major duodenal papilla (placebo)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 326

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 326
Study: 10714841

Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 5%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5%
Number of subjects: 70
Study: 9014067

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 165

Group type: COMPARATOR
Intervention: Heparin-dihydroergotamine 0.5 mg + 5,000 IU twice a day
Number of subjects: 165
Study: 1396108

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.4 mg or 0.8 mg/70 kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.4 mg or 0.8 mg/70 kg) + Naloxone (0.4 mg or 0.8 mg/70 kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3888241

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 or 2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study: 30864824

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupuncture stimulation (TEAS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mock transcutaneous electrical acupuncture stimulation (MTEAS)
Number of subjects: 122
Study: 28214653

Group type: EXPERIMENTAL
Intervention: NACT followed by CCRT (cisplatin 80 mg/m2 d1 and fluorouracil 800 mg/m2 civ d1‐5 for two cycles before CCRT)
Number of subjects: 476

Group type: COMPARATOR
Intervention: CCRT alone (cisplatin 80 mg/m2 every 3 weeks concurrently with radiotherapy)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: NACT followed by CCRT
Number of subjects: 476

Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 476
Study: 25277597

Group type: EXPERIMENTAL
Intervention: Cyclosporine treatment for 2 years
Number of subjects: 46
Study: 23179472

Group type: EXPERIMENTAL
Intervention: CicloMulsion(®)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sandimmune(®)
Number of subjects: 52
Study: 21684425

Group type: EXPERIMENTAL
Intervention: Pandemic live attenuated influenza vaccine (PLAIV) against the influenza A (H1N1) virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H5N2 pandemic live attenuated influenza vaccine (PLAIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seasonal live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study: 18307373

Group type: EXPERIMENTAL
Intervention: Duloxetine (10 mg IV infusion over 30 minutes or 60 mg orally) with fluvoxamine (100 mg orally once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg orally twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg orally once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duloxetine (60 mg orally)
Number of subjects: 0
Study: 17000242

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin therapy (enoxaparin sodium)
Number of subjects: 120
Study: 12708126

Group type: EXPERIMENTAL
Intervention: 0.5% centbucridine hydrochloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% centbucridine hydrochloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% lignocaine hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unanaesthetized control
Number of subjects: 60
Study: 10509768

Group type: EXPERIMENTAL
Intervention: Breakfast cereal (80 g for men, 60 g for women) consumed at breakfast for six weeks
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual breakfast (control) for six weeks
Number of subjects: 224
Study: 8948303

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) and parenteral gold therapy (PGT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo and parenteral gold therapy (PGT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 40
Study: 1746414

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard treatment (placebo)
Number of subjects: 204
Study: 7102441

Group type: EXPERIMENTAL
Intervention: Deprivation condition (anticipated 4-hour food deprivation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-restraint group
Number of subjects: 50

Group type: COMPARATOR
Intervention: No deprivation condition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-restraint group
Number of subjects: 50
Study: 30623309

Group type: EXPERIMENTAL
Intervention: Test dentifrice (calcium silicate, sodium phosphate, 1450 ppm sodium monofluorophosphate)
Number of subjects: 256
Study: 28452665

Group type: EXPERIMENTAL
Intervention: Home-delivered cognitive-behavioral therapy (CBT) for depression
Number of subjects: 134

Group type: COMPARATOR
Intervention: Minimal support control condition
Number of subjects: 134
Study: 27061727

Group type: EXPERIMENTAL
Intervention: Nonconstrained cervical arthroplasty
Number of subjects: 37
Study: 24381276

Group type: EXPERIMENTAL
Intervention: IC training on an adaptive version of the stop-signal task (SST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active sham-training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IC training
Number of subjects: 60
Study: 21791142

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.7 g daily for 3 months)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 206
Study: 19383589

Group type: EXPERIMENTAL
Intervention: 16 degrees C hypothermia (group I)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 22 degrees C hypothermia (group II)
Number of subjects: 55
Study: 17760732

Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting increased abdominal girth
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting sunken cheeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting reduced diameter of the legs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting increased neck girth
Number of subjects: 100
Study: 15886433

Group type: EXPERIMENTAL
Intervention: Custom data acquisition system (DA) - data collected every minute
Number of subjects: 16

Group type: COMPARATOR
Intervention: Medical record (MR) - data collected hourly
Number of subjects: 16
Study: 12492626

Group type: EXPERIMENTAL
Intervention: Palmitic acid (10% of energy) with varying levels of linoleic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trans fatty acids
Number of subjects: 0
Study: 10321136

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9800145

Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 19.2 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine 0.05 mg/kg
Number of subjects: 0
Study: 1863121

Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Low frequency positive pressure ventilation (LFPPV)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV) in infants with hyaline membrane disease
Number of subjects: 346

Group type: COMPARATOR
Intervention: Low frequency positive pressure ventilation (LFPPV) in infants with hyaline membrane disease
Number of subjects: 346
Study: 6193350

Group type: EXPERIMENTAL
Intervention: 10 mg MDL‐899
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg MDL‐899 with 100 mg atenolol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31172750

Group type: EXPERIMENTAL
Intervention: Randomized control pulses for quantum sensing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonrandomized pulse sequences
Number of subjects: 0
Study: 29653344

Group type: EXPERIMENTAL
Intervention: Specialized comprehensive early intervention care (EIP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study: 26158873

Group type: EXPERIMENTAL
Intervention: Epithelial gap geometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical coupling between actomyosin cable contraction and cell crawling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computational modelling
Number of subjects: 0
Study: 23688137

Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment group (daily olfactory/tactile stimulation and paired sensory exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enriched group
Number of subjects: 0
Study: 21833000

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2232

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2232
Study: 18246334

Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease (AD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study: 16946455

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI) of antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 0
Study: 12723462

Group type: EXPERIMENTAL
Intervention: Trazodone with low-dose ritonavir (200 mg each, four doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Trazodone with low-dose ritonavir
Number of subjects: 10

Group type: COMPARATOR
Intervention: Trazodone plus placebo
Number of subjects: 10
Study: 10677399

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 38
Study: 8788541

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka and tonic to achieve a blood alcohol level of 0.08%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonalcohol beverage (tonic only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20
Study: 1299797

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study: 6490928

Group type: EXPERIMENTAL
Intervention: Paradoxical interventions
Number of subjects: 12
Study: 30371800

Group type: EXPERIMENTAL
Intervention: Chemotherapy + goserelin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 218
Study: 29862258

Group type: EXPERIMENTAL
Intervention: Mini-trampoline physical activity (20 min after school, 5 days/week for 10 weeks)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (same classes and care service, no extra trampoline training)
Number of subjects: 57
Study: 26690356

Group type: EXPERIMENTAL
Intervention: Letrozole (0.1 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cabergoline (100 µg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24293176

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 177
Study: 22836812

Group type: EXPERIMENTAL
Intervention: Mailed intervention materials (patient osteoporosis brochure and a letter explaining how to self-schedule a DXA scan)
Number of subjects: 2997

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2997
Study: 20217128

Group type: EXPERIMENTAL
Intervention: CD34+ selected peripheral blood progenitor cells (PBPC) from related allogeneic donors (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors (group B)
Number of subjects: 50
Study: 17351370

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily for 4 weeks
Number of subjects: 13
Study: 16318148

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion plus Chinese medicine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Simple Chinese medicine
Number of subjects: 79
Study: 12077689

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional open vein harvesting (OVH)
Number of subjects: 140
Study: 9706951

Group type: EXPERIMENTAL
Intervention: RS‐25259 30 microg/kg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RS‐25259 0.3-30 microg/kg
Number of subjects: 218

Group type: COMPARATOR
Intervention: RS‐25259
Number of subjects: 218
Study: 9773700

Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone and 10 mL 0.5% bupivacaine (group OB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interscalene plexus block (group IPB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10 mL 0.5% bupivacaine (group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 2496213

Group type: COMPARATOR
Intervention: Low-dose calcium and phosphorus (5 mM each; 20 mg/dl of Ca and 15.5 mg/dl of P)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose calcium and phosphorus (15 mM each; 60 mg/dl of Ca and 46.5 mg/dl of P)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (low and high-dose)
Number of subjects: 25
Study: 1006147

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Moderate exercise in supine position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting supine position
Number of subjects: 6
Study: 31203062

Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR) based planning (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2-dimensional standard planning route (Group A)
Number of subjects: 60
Study: 28830511

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 25654750

Group type: EXPERIMENTAL
Intervention: Experiential training in outer and middle ear screening
Number of subjects: 36
Study: 23808950

Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method
Number of subjects: 137

Group type: COMPARATOR
Intervention: Smear cytology
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for bile duct cancer
Number of subjects: 137

Group type: COMPARATOR
Intervention: Smear cytology for bile duct cancer
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for pancreatic head cancer
Number of subjects: 137

Group type: COMPARATOR
Intervention: Smear cytology for pancreatic head cancer
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for gallbladder cancer
Number of subjects: 137

Group type: COMPARATOR
Intervention: Smear cytology for gallbladder cancer
Number of subjects: 137
Study: 21666556

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone administered in 100 mL of physiologic saline given intravenously 20 minutes before anesthesia induction
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2 mL NaCl 0.9% in 100 mL of physiologic saline (control group)
Number of subjects: 70
Study: 19417877

Group type: EXPERIMENTAL
Intervention: Ketoprofen (50 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (25 mg)
Number of subjects: 51
Study: 16394842

Group type: EXPERIMENTAL
Intervention: Generic nevirapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Brand name nevirapine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Generic lamivudine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Brand name lamivudine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Generic zidovudine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Brand name zidovudine
Number of subjects: 15
Study: 14968598

Group type: EXPERIMENTAL
Intervention: PCEA with background infusion (3 ml PCEA, lock out 30 min, continuous infusion 5 ml/hr)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Infuser group (continuous infusion 5 ml/hr)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PCEA with background infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Infuser group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PCEA group
Number of subjects: 90
Study: 11816957

Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3% polidocanol
Number of subjects: 100
Study: 9160657

Group type: EXPERIMENTAL
Intervention: Interferon alpha2b 3 million U three times weekly for 12 months
Number of subjects: 107

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 107
Study: 7695058

Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg once a day
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 3302705

Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline alone daily for two years)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among less disabled patients (Kurtzke score 0 to 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo among less disabled patients (Kurtzke score 0 to 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among more disabled patients (Kurtzke score 3 to 6)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo among more disabled patients (Kurtzke score 3 to 6)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among less disabled patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo among less disabled patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among more disabled patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo among more disabled patients
Number of subjects: 50
Study: 30111298

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) interventions, mean of 2.5 MI interventions per week per patient
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program including training of staff in MI and improvements of facilities for physical exercise
Number of subjects: 83
Study: 27550085

Group type: EXPERIMENTAL
Intervention: Combined intervention group (CIG; n = 66)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Care as usual group (CAUG; n = 30)
Number of subjects: 96
Study: 23892777

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg/day for first 3 days, then 1 mg/day for 4 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22802308

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day) for 3 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg per day) for 3 months
Number of subjects: 44
Study: 19874198

Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odanacatib (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Odanacatib and Placebo
Number of subjects: 0
Study: 18310545

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone and rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: High dose methylprednisolone alone
Number of subjects: 0
Study: 15847901

Group type: EXPERIMENTAL
Intervention: Safehip hip protectors
Number of subjects: 109

Group type: COMPARATOR
Intervention: HipSaver hip protectors
Number of subjects: 109

Group type: COMPARATOR
Intervention: Safehip and HipSaver hip protectors
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Residents in a home for the elderly mentally infirm
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Residents with a low Barthel score (12 or less)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Residents with a history of falls in the last 12 months
Number of subjects: 109
Study: 12209697

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha2b (HDI)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low-dose interferon alpha2b (LDI)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard observation (OBS)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha2b (HDI) and Low-dose interferon alpha2b (LDI)
Number of subjects: 148
Study: 10522576

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (15 mL bupivacaine 0.5%) and 1 mL normal saline i.v. (FNB group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30 mg (1 mL) ketorolac i.v. (KT group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo femoral nerve block (15 mL normal saline) and 1 mL normal saline i.v. (PL group)
Number of subjects: 90
Study: 7747819

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 beta (rhuIL-1 beta) at high concentration (1.0 micrograms/cm2/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-1 beta (rhuIL-1 beta) at low (0.01 micrograms/cm2/day) and medium (0.1 micrograms/cm2/day) concentrations
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tissue culture measurements from pressure ulcer biopsies
Number of subjects: 26
Study: 1970552

Group type: EXPERIMENTAL
Intervention: 200 mg of an i.v. immunoglobulin preparation (ivIg)/kg body weight every other week
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40